Identification and experimental validation of CD74, PGLYRP1, and TXN as potential biomarkers in rheumatoid arthritis: an integrative bulk and ScRNA-seq study - Scorecard - MDSpire
Advertisement
Identification and experimental validation of CD74, PGLYRP1, and TXN as potential biomarkers in rheumatoid arthritis: an integrative bulk and ScRNA-seq study
Clinical Scorecard: Discovery and experimental confirmation of CD74, PGLYRP1, and TXN as promising biomarkers for rheumatoid arthritis: a comprehensive analysis using bulk and single-cell RNA sequencing
At a Glance
Category
Detail
Condition
Rheumatoid Arthritis
Key Mechanisms
Chronic joint inflammation, immune response, and redox processes.
Target Population
Individuals with rheumatoid arthritis, particularly those with progressive joint damage.
Care Setting
Clinical and research settings utilizing transcriptomic data and biomarker validation.
Key Highlights
CD74, PGLYRP1, and TXN identified as potential biomarkers for RA.
Single-cell RNA sequencing revealed myeloid cells as a key population.
Biomarkers showed significant expression changes in RA clinical samples.
Integration of bulk and single-cell RNA sequencing provided comprehensive insights.
Molecular docking confirmed binding affinities of compounds to biomarkers.
Guideline-Based Recommendations
Diagnosis
Utilize CD74, PGLYRP1, and TXN as biomarkers for RA diagnosis.
Management
Consider the role of identified biomarkers in developing precision medicine strategies.
Monitoring & Follow-up
Monitor biomarker levels in clinical samples to assess disease progression.
Risks
Current treatments may have adverse effects; new biomarkers could guide safer therapies.
Patient & Prescribing Data
Patients diagnosed with rheumatoid arthritis.
Existing treatments include NSAIDs, corticosteroids, DMARDs, and biologics, but they have limitations.
Clinical Best Practices
Integrate transcriptomic data for a comprehensive understanding of RA.
Validate biomarker findings in clinical samples for reliability.
Utilize single-cell RNA sequencing to uncover cellular heterogeneity in RA.
